CVS Health reported a strong Q2 2025, with adjusted earnings per share of $1.81, surpassing Wall Street estimates of $1.46. Total revenue rose 8.4% to $98.9 billion, exceeding expectations of $94.7 billion. The performance was driven by a significant recovery in its Aetna insurance business, which saw a medical loss ratio of 89.9%, better than the anticipated 91.16%. Strong retention at CVS Caremark and growth in CVS Pharmacy also contributed. The company raised its full-year adjusted EPS guidance to $6.30-$6.40 from $6.00-$6.20 and increased its cash flow from operations forecast to at least $7.5 billion from $7 billion. However, CVS plans to exit the Affordable Care Act individual exchange market in 2026 due to ongoing underperformance.
By Satish Mehra
Satish Mehra (author and owner) Welcome to REALNEWSHUB.COM Our team is dedicated to delivering insightful, accurate, and engaging news to our readers. At the heart of our editorial excellence is our esteemed author Mr. Satish Mehra. With a remarkable background in journalism and a passion for storytelling, [Author’s Name] brings a wealth of experience and a unique perspective to our coverage.